– USA, MA – Bruker Corporation (Nasdaq: BRKR) announced the appointment of Laura Francis to its board as an independent director, effective as of February 18, 2025.
Frank Laukien, chairman, president and CEO said: “We warmly welcome Laura to our board of directors. Her experience as a public company medtech CEO, along with her CFO and COO experience in both the medtech and life science tools industries is going to be very valuable in guiding Bruker’s profitable growth and strategy execution. Laura is an impressive and accomplished leader, and she is a wonderful addition to our board.”
Laura Francis should also join the Audit Committee as a financial expert after the AGM at the end of May 2025.
About Laura Francis
Laura Francis is CEO and a Board Member of SI-BONE, Inc. (Nasdaq: SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the CFO and COO of the company. Before joining SI-BONE, Laura Francis held other executive and leadership roles with public and private life science companies, including Bruker Corporation, as well as Auxogyn, now part of Progyny (Nasdaq: PGNY), and Promega Corporation. Earlier in her career, she was an Engagement Manager with McKinsey & Company and an Audit Manager with Coopers & Lybrand, now PricewaterhouseCoopers.
Laura Francis previously also was a board member of Shockwave Medical, Inc. (Nasdaq: SWAV), a medical device company, where she served as audit committee chair and compensation committee member.
“I am honored to join the Board of Directors at Bruker Corporation, a company I deeply respect and had the privilege of serving as CFO earlier in my career,” said Laura Francis. “I look forward to contributing to Bruker’s continued innovation and growth in the life sciences and diagnostics industries.”
Laura Francis earned a B.B.A. in Accounting and Finance from the University of Wisconsin and an M.B.A. from Stanford University. She is a Certified Public Accountant (inactive) in the State of California.
About Bruker CorporationBruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as clinical microbiology and molecular diagnostics.
For more: https://www.bruker.com/en.html
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.